Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503507 | 0.84 | CA1 (0.61) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL19130846 | 0.83 | KEAP1 (0.39) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL13469362 | 0.83 | CA1 (0.40) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL28522302 | 0.81 | CA1 (0.58) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL29154297 | 0.81 | CA1 (0.58) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL31490367 | 0.81 | GAA (0.39) | KEAP1KMT2AKDM4EGFERRXFP1 | |
| SCHEMBL13469364 | 0.78 | CA1 (0.50) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL22832001 | 0.76 | TSHR (0.41) | CA1CA2CA4KDM4ECA9 | |
| SCHEMBL29562023 | 0.76 | TSHR (0.41) | CA1CA2CA4KDM4ECA9 | |
| SCHEMBL5341471 | 0.76 | CA1 (0.46) | CA1CA2CA4KEAP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113604194-A | Modified epoxy resin binder for stone and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-113583606-A | Stone binder of polyphenyl ether modified epoxy resin and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-113528068-A | Double-component stone crack sealer and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-113462338-A | Stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-113403015-A | Double-component stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-09-17 | — | — | CN | claimed |
| EP-1973883-B1 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-10-08 | — | — | US | claimed |
| EP-1973883-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | Biotica Technology Limited (GB) | 2008-10-01 | — | — | EP | claimed |
| EP-1928837-A2 | 18,21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | Biotica Technology Limited (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2008056188-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-05-15 | — | — | WO | claimed |
| WO-2007128829-A2 | 18,21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-15 | — | — | WO | claimed |
| JP-3093758-A | — | — | None | — | — | JP | disclosed |
| CN-113604194-A | Modified epoxy resin binder for stone and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-113583606-A | Stone binder of polyphenyl ether modified epoxy resin and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113528068-A | Double-component stone crack sealer and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| JP-H0393758-A | FLUOROBENZENE DERIVATIVE AND ITS PRODUCTION | IMPERIAL CHEM IND PLC <ICI> | 1991-04-18 | — | — | JP | disclosed |
| EP-0415585-A1 | Fluorobenzene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BCL3, BECN1, CD22 | CA1 2746/4885CA2 3474/4885CA4 1603/4885 |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BCL6, BCL3, AQP4 | CA1 3205/4885CA2 3632/4885CA4 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.